Background: Toxic epidermal necrolysis (TEN) is a rare, severe adverse drug reaction. Stevens-Johnson syndrome (SJS) represents the milder end of the spectrum. The exact pathogenesis of TEN and SJS is still unknown. Many drugs, including prednisolone, cyclosporin, and intravenous immunoglobulin (IVIG), have been used in an attempt to halt the disease process. The use of phenytoin as a prophylactic anticonvulsant after brain surgery, particularly for brain tumors, is a common practice, regardless of whether the patient has a previous history of convulsions. This treatment policy assumes that the benefits exceed the risks.
Case: In this paper, we describe a young patient who underwent a total removal of an intracerebral cavernous hemangioma following development of SJS after taking phenytoin postoperatively.
Conclusion: We suggest that the practice of routine use of phenytoin following brain surgery should be re-evaluated because the treatment may be neither essential nor without side effects.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1055/s-0032-1330112 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
An Acetylcholine M1 Receptor-Positive Allosteric Modulator (TAK-071) in Parkinson Disease With Cognitive Impairment: A Phase 2 Randomized Clinical Trial.
JAMA Neurol
January 2025
Takeda Development Center Americas, Inc, Cambridge, Massachusetts.
Importance: Fall risk and cognitive impairment are prevalent and burdensome in Parkinson disease (PD), requiring efficacious, well-tolerated treatment.
Objective: To evaluate the safety and efficacy of TAK-071, a muscarinic acetylcholine M1 positive allosteric modulator, in participants with PD, increased fall risk, and cognitive impairment.
Design, Setting, And Participants: This phase 2 randomized double-blind placebo-controlled crossover clinical trial was conducted from October 21, 2020, to February 27, 2023, at 19 sites in the US.
Oral Antibiotics and Cutaneous Adverse Drug Reactions-Reply.
JAMA
January 2025
Division of General Internal Medicine and Clinical Pharmacology and Toxicology, University of Toronto, Toronto, Ontario, Canada.
Oral Antibiotics and Cutaneous Adverse Drug Reactions.
JAMA
January 2025
Department of Clinical and Environmental Allergology, Jagiellonian University Medical College, Kraków, Poland.
Intravenous Pump Flow Accuracy: A Systematic Review.
J Infus Nurs
December 2024
Author Affiliations: Elaine Marieb College of Nursing, Elaine Marieb Center for Nursing & Engineering Innovation, University of Massachusetts Amherst, Amherst, Massachusetts.
Intravenous pumps (IVPs) deliver IV medications to millions of acute care patients each year and result in many adverse events reported to the US Food and Drug Administration (FDA). Although the use of IVPs has improved overall safety, there are still high rates of error that risk the safety of all patients, especially those of advanced age and those suffering from critical illness. Most of the documented errors are based on clinician reports, although there is reason to believe that errors due to flow rate inaccuracy go undetected and unreported.
View Article and Find Full Text PDFTargeted Covalent Nanodrugs Reinvigorate Antitumor Immunity and Kill Tumors via Improving Intratumoral Accumulation and Retention of Doxorubicin.
ACS Nano
January 2025
Molecular Science and Biomedicine Laboratory (MBL), State Key Laboratory of Chemo/Biosensing and Chemometrics, College of Chemistry and Chemical Engineering, Aptamer Engineering Center of Hunan Province, Hunan University, Changsha, Hunan 410082, China.
Specifically improving the intratumoral accumulation and retention and achieving the maximum therapeutic efficacy of small-molecule chemotherapeutics remains a considerable challenge. To address the issue, we here reported near-infrared (NIR) irradiation-activatable targeted covalent nanodrugs by installing diazirine-labeled transferrin receptor 1 (TfR1)-targeted aptamers on PEGylated phospholipid-coated upconversion nanoparticles followed by doxorubicin loading. Targeted covalent nanodrugs recognized and then were activated to covalently cross-link with TfR1 on cancer cells by 980 nm NIR irradiation.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!